Riet Rosseel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Riet Rosseel has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Kristin Verbeke
Translational Research center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium
3 shared publications - Boushra Dalile
Brain Research on Affective Mechanisms (BRAMLab), Research Unit Brain & Cognition, Faculty of Psychology and Educational Sciences, KU Leuven, Leuven, Belgium
1 shared publication - Bram Van Holm
KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical and Epidemiological Virology, Rega Institute, Leuven, 3000, Belgium
1 shared publication - Christophe M. Courtin
Laboratory of Food Chemistry and Biochemistry, Department of Microbial and Molecular Systems, KU Leuven, Leuven, Belgium
1 shared publication - Dina Satriawan
Translational Research Center in Gastrointestinal Disorders (TARGID), KU Leuven, ON1 box 701, Herestraat 49, B-3000, Leuven, Belgium
1 shared publication - Georgia Chatonidi
Translational Research Center in Gastrointestinal Disorders (TARGID), KU Leuven, ON1 box 701, Herestraat 49, B-3000, Leuven, Belgium
1 shared publication
Latest Publications
- Open Access
- 10 August 2026
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 124 (4)
Small intestinal compared with colonic short-chain fatty acid delivery drives distinct systemic concentrations and endocrine responses in humans: a randomized, crossover trial
- 10 August 2026
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 124 (4)
Open AccessSmall intestinal compared with colonic short-chain fatty acid delivery drives distinct systemic concentrations and endocrine responses in humans: a randomized, crossover trial
- Open Access
- 1 February 2024
- Published by MDPI AG in Proceedings
- Vol. 91 (1) , 176
The Contribution of Short-Chain Fatty Acids to Health Benefits May Depend on the Site of Absorption: A Mechanistic Study Design
The fermentation of dietary fibres in the human colon generates short-chain fatty acids (SCFAs) that potentially mediate the health benefits associated with high fibre intake. In the colonic lumen, SCFAs support gut health and stimulate the release of the appetite-regulating hormones glucagon-like peptide 1 (GLP-1) and peptide-YY (PYY). In addition, SCFAs act as fuel for colonocytes and serve as precursors for substrate metabolism in the liver. The SCFAs that ultimately reach the systemic circulation may influence physiological processes in organs at a distance. Yet, when consuming plant-based fermented foods containing SCFAs, the SCFAs are absorbed in the small intestine and will not reach the colon, which might affect their physiological effects. We hypothesise that, compared to colonic delivery, a larger fraction of SCFAs will reach the systemic circulation and that the stimulation of gut hormone release will be less pronounced. To test this hypothesis, we designed two randomised crossover human intervention studies in healthy participants in which SCFAs will be targeted either to the small intestine (test day 1) or colon (test day 2) using standard capsules or capsules with a colon delivery coating, respectively. Study 1 will assess the systemic bioavailability of postprandial concentrations of labelled SCFAs after oral administration of stable isotope 13C-labelled SCFAs and intravenous administration of ²H-labelled SCFAs. In study 2, postprandial concentrations of GLP-1 and PYY, glucose, and insulin will be quantified after the administration of capsules with unlabelled SCFAs. These studies will clarify the importance of the site of administration on the kinetics of SCFAs and the gut hormone release that will contribute to elucidating the role of SCFAs as health-supporting metabolites.
- 1 February 2024
- Published by MDPI AG in Proceedings
- Vol. 91 (1) , 176
Open AccessThe Contribution of Short-Chain Fatty Acids to Health Benefits May Depend on the Site of Absorption: A Mechanistic Study Design
The fermentation of dietary fibres in the human colon generates short-chain fatty acids (SCFAs) that potentially mediate the health benefits associated with high fibre intake. In the colonic lumen, SCFAs support gut health and stimulate the release of the appetite-regulating hormones glucagon-like peptide 1 (GLP-1) and peptide-YY (PYY). In addition, SCFAs act as fuel for colonocytes and serve as precursors for substrate metabolism in the liver. The SCFAs that ultimately reach the systemic circulation may influence physiological processes in organs at a distance. Yet, when consuming plant-based fermented foods containing SCFAs, the SCFAs are absorbed in the small intestine and will not reach the colon, which might affect their physiological effects. We hypothesise that, compared to colonic delivery, a larger fraction of SCFAs will reach the systemic circulation and that the stimulation of gut hormone release will be less pronounced. To test this hypothesis, we designed two randomised crossover human intervention studies in healthy participants in which SCFAs will be targeted either to the small intestine (test day 1) or colon (test day 2) using standard capsules or capsules with a colon delivery coating, respectively. Study 1 will assess the systemic bioavailability of postprandial concentrations of labelled SCFAs after oral administration of stable isotope 13C-labelled SCFAs and intravenous administration of ²H-labelled SCFAs. In study 2, postprandial concentrations of GLP-1 and PYY, glucose, and insulin will be quantified after the administration of capsules with unlabelled SCFAs. These studies will clarify the importance of the site of administration on the kinetics of SCFAs and the gut hormone release that will contribute to elucidating the role of SCFAs as health-supporting metabolites.